TC
EIGR

TFS Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

TFS Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-404
Closed -$96K – 395
2017
Q2 		$96K Buy
+404
New +$91.8K 0.04% 553
2016
Q1 		– Sell
-63
Closed -$41K – 1120
2015
Q4 		$41K Sell
63
-102
-62% -$57.7K ﹤0.01% 715
2015
Q3 		$78K Sell
165
-420
-72% -$223K 0.01% 821
2015
Q2 		$332K Buy
+585
New +$1.62M 0.03% 647
2015
Q1 		– Sell
-93
Closed -$821K – 1158
2014
Q4 		$821K Buy
93
+40
+75% +$232K 0.08% 422
2014
Q3 		$248K Buy
53
+23
+77% +$122K 0.02% 813
2014
Q2 		$216K Buy
+30
New +$150K 0.02% 923

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TFS Capital's EIGR Position: Q3 2017 in Review

TFS Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2017, closing a stake of 404 shares — an estimated $96K sold.

TFS Capital first reported a position in EIGR in Q2 2014 and held it in 7 quarters. The position peaked at $821K in Q4 2014. 33 funds tracked by Wall St. Rank hold EIGR as of Q3 2017.

  • TFS Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 404 Eiger BioPharmaceuticals, Inc. shares in Q3 2017, an estimated $96K.
  • TFS Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 7 quarters.
  • TFS Capital's Eiger BioPharmaceuticals, Inc. position peaked at $821K in Q4 2014.
  • 33 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.